Dobutamine Added to Norepinephrine Lowers Postoperative Kidney Injury in Septic Shock
Intraoperative dobutamine combined with norepinephrine reduced the risk of new-onset or worsening acute kidney injury within 7 days after surgery in adults with septic shock undergoing surgical source control. The finding is clinically consequential because postoperative renal injury in septic shock can quickly escalate into prolonged organ failure, longer intensive care use, and a more complicated recovery trajectory after source control has already been achieved.
This randomized, open-label trial enrolled 584 adults across 39 tertiary hospitals in China between June 2024 and August 2025, with follow-up ending on November 15, 2025. The median age was 67.5 years, and 32.9% of participants were female. Patients were assigned intraoperative intravenous dobutamine up to 5 µg/kg/min plus norepinephrine or norepinephrine alone. The trial asked a narrow but clinically important question: whether adding an inotrope during surgery could protect the kidney in a setting where shock physiology, inflammation, vasoplegia, and impaired perfusion often collide.
The answer favored the combination arm. New-onset or worsening acute kidney injury within 7 postoperative days occurred in 22.8% of patients receiving dobutamine plus norepinephrine, compared with 34.7% in those receiving norepinephrine alone. The adjusted risk ratio was 0.64, with a 95% CI of 0.49 to 0.83. In practical terms, the renal signal moved in a direction that suggests more than a marginal physiologic effect: improving myocardial performance and forward flow during source-control surgery may have helped preserve renal perfusion at the exact moment when perfusion pressure and cardiac output are most fragile.
Renal Protection Appeared Most Clearly in More Severe AKI Stages
The benefit was not confined to the broad composite endpoint. Stage 2 and stage 3 AKI were both lower in the dobutamine plus norepinephrine group. Stage 2 AKI occurred in 4.8% versus 9.9% of patients, with an adjusted risk ratio of 0.48. Stage 3 AKI occurred in 7.9% versus 13.6%, with an adjusted risk ratio of 0.56. Those separations matter because higher-stage AKI is the form most likely to translate into dialysis, prolonged hospitalization, and persistent kidney dysfunction after the acute septic episode has passed.
The physiology fits the bedside observation. Norepinephrine restores vascular tone and supports perfusion pressure, but it does not directly strengthen a failing ventricle. Dobutamine, by contrast, augments cardiac contractility and can improve forward blood flow when septic shock has depressed the heart’s pumping capacity or when distributive shock is being complicated by occult myocardial dysfunction. In a patient whose kidneys are already vulnerable from systemic inflammation, capillary leak, and hypoperfusion, a small rise in effective renal blood flow may be enough to change the renal trajectory over the next several postoperative days.
Early Hemodynamic Signals Favored the Combination Arm
Two secondary outcomes moved in the same direction. SOFA scores on postoperative day 1 were lower in the dobutamine plus norepinephrine group, with an adjusted difference of -0.53. Urine output 1 hour after intervention was also higher, with an adjusted difference of 0.55 mL/kg/h. Those are not cosmetic changes. Early urine output remains one of the most immediate bedside markers that renal perfusion and filtration are improving rather than deteriorating, and a lower SOFA score suggests a less severe global organ dysfunction burden in the early postoperative window.
Still, the trial did not produce a sweeping improvement across the full secondary outcome set. Nine of 11 secondary outcomes did not differ significantly between groups. The renal benefit therefore appears focused rather than universal, which is exactly how a hemodynamic intervention often behaves when it helps one vulnerable organ system without changing every downstream measure of critical illness.
Tachycardia was more common with dobutamine plus norepinephrine. That safety signal is expected for a beta-adrenergic inotrope and should be interpreted as part of the trade-off rather than an unexpected toxicity. In septic shock, a higher heart rate can be tolerated in some patients, but persistent tachycardia also raises myocardial oxygen demand and can be problematic in those with ischemia or limited cardiac reserve. The trial’s results do not eliminate that concern; they place it beside a measurable reduction in kidney injury.
Why the Kidney Signal May Have Emerged During Source Control
Surgical source control is a uniquely unstable period for a patient with septic shock. An infected abdomen, biliary tree, soft tissue focus, or other surgical source often drives vasodilation, inflammatory mediator release, and evolving organ dysfunction. During the operation, anesthetic depth, fluid shifts, vasopressor use, and myocardial performance all influence whether the kidney receives enough effective perfusion to avoid acute tubular stress. In that context, a combined vasopressor and inotrope strategy is biologically plausible because it targets both pressure and flow.
The trial design also matters. It was open-label, and the intervention was limited to the intraoperative period, so the observed renal benefit should not be overgeneralized to all septic shock management or to postoperative care outside the operating room. The absence of significant differences in most secondary outcomes argues against broad systemic benefit beyond the kidney-focused signal captured in this cohort. Even so, the primary endpoint and the severity-stratified AKI findings suggest a real physiologic effect rather than a statistical artifact.
Adults with septic shock undergoing surgery are a high-risk population in which clinicians must often choose between preserving hemodynamics and avoiding catecholamine burden. This trial suggests that, for selected patients, adding dobutamine to norepinephrine may improve the postoperative renal course instead of merely increasing pharmacologic complexity. The trade-off is tachycardia, and the benefit is measured in fewer cases of AKI over the first postoperative week.
The study was registered at ClinicalTrials.gov as NCT06462313. Its main limitation for bedside practice is not the presence of a renal signal, but the narrow scope of the intervention window and the lack of broader outcome separation beyond AKI and a few early physiologic measures. The unanswered clinical question is how long the benefit persists after surgery and whether the same strategy improves patient-centered outcomes such as dialysis use, ICU duration, or survival in routine practice.